Daniel Patten
Family Medicine · Preston, IDNPI 1245490390
Payments from drug & device makers
Across 118 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$961
- Novo Nordisk$215
- Lilly USA, LLC$118
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$109
- Amgen$60
- Phathom Pharmaceuticals, Inc.$60
- plus $331 from 16 others
What the payments were for
- Food & beverage$1,854100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $961 |
| Novo Nordisk | 14 | $215 |
| Lilly USA, LLC | 9 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $109 |
| Amgen | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Corium, LLC | 2 | $30 |
| Genentech USA, Inc. | 2 | $28 |
| Pfizer | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Medtronic | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Innocoll Pharmaceuticals Limited | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,854 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $43,879 |
| JardianceEmpagliflozin | 55 | $37,969 |
| OzempicSemaglutide | 28 | $31,588 |
| EliquisApixaban | 56 | $29,400 |
| FarxigaDapagliflozin Propanediol | 41 | $21,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,956 |
| Gabapentin | 50 | $1,599 |
| Levothyroxine Sodium | 120 | $1,468 |
| Potassium Chloride | 76 | $1,394 |
| Lisinopril | 116 | $1,288 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $1,233 |
| Omeprazole | 116 | $1,194 |
| Rosuvastatin Calcium | 65 | $1,137 |
| Esomeprazole Magnesium | 24 | $990 |
| Fluoxetine Hcl | 83 | $960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $118 | $43,87942 claims |
| Novo NordiskOzempic | $215 | $31,58828 claims |
| PfizerEliquis | $27 | $29,40056 claims |
| GSKTrelegy Ellipta | $13 | $13,95618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 803 family medicine providers in Idaho.
Other family medicine in Preston
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.